Mereo BioPharma Group plc, a UK-based biopharmaceutical firm, is expanding its portfolio of products aimed at treating oncology and rare diseases. The company's lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, is currently being tested in Phase 1b clinical trials for use in tumors. Other products in Mereo's pipeline include Navicixizumab (OMP-305B83) for the treatment of late line ovarian cancer, Acumapimod (BCT-197) for acute exacerbations of chronic obstructive pulmonary disease, and Leflutrozole (BGS-649) for the treatment of hypogonadotropic hypogonadism. Mereo also has rare disease product candidates, such as Setrusumab (BPS-804) for osteogenesis imperfecta and Alvelestat (MPH-966) for Alpha-1 anti-trypsin deficiency. Mereo BioPharma Group has a collaboration with The University of Texas MD Anderson Cancer Center to test the anti-TIGIT therapeutic antibody candidate etigilimab and a licensing agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.
Mereo BioPharma Group plc's ticker is MREO
The company's shares trade on the NASDAQ stock exchange
They are based in London, England
There are 11-50 employees working at Mereo BioPharma Group plc
It is https://www.mereobiopharma.com/
Mereo BioPharma Group plc is in the Healthcare sector
Mereo BioPharma Group plc is in the Biotechnology industry
The following five companies are Mereo BioPharma Group plc's industry peers: